Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.
As of June 30, 2025, the company's diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory).
The company has a pan-India marketing and distribution network with 2,671 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.
The company has two manufacturing facilities, located in the states of Gujarat with an aggregate installed capacity for formulations of 1,285.44 million units per annum.
Competitive Strength:
| Investory Category | Subscription Percentage | Amount Raised (₹ Crores) |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | 50% | 3252490 crores |
| Non-Institutional Investors (NIIs | 15% | 975747 crores |
| Retail Individual Investors (RIIs) | 35% | 2276743 crores |
| Allotment Date | Listing Date |
|---|---|
| 11 Dec '25 | 15 Dec '25 |
| Minimum Lot Size | 14 shares |
| Maximum Lot Size (Retail) | 462 shares |
The lot size of Corona Remedies Ltd ipo has been designed to ensure broad participation while maintaining optimal price discovery.